Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-KIDNEY: BI 690517 plus empagliflozin in chronic kidney disease
jRCT2031250295Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in chronic kidney disease (CKD) comparing Run-in: placebo matching BI 690517 + empagliflozin, BI 690517 + empagliflozin and Placebo + empagliflozin (3 arms). Primary endpoint: Primary composite cardiorenal outcome. Started Dec 2025; status: active, not recruiting.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031250295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250295.